Based on ratings from 3 stock analysts, the Quidel Corp stock price is expected to increase by 51.65% in 12 months. This is calculated by using the average 12-month stock price forecast for Quidel Corp. The lowest target is $37.00 and the highest is $81.00. Please note analyst price targets are not guaranteed and could be missed completely.
About 3 Wall Street analysts have assignedQDEL 1 buy ratings, 1 hold ratings, and 1 sell ratings. This means that analysts expect Quidel Corp to sell. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on QDEL. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
casey woodring J.P. Morgan | Sell | $37.0 | downgraded | Feb 14, 2024 |
conor mcnamara RBC Capital | Buy | $81.0 | maintained | Feb 14, 2024 |
alexander nowak Craig-Hallum | Buy | None | rated | Dec 21, 2023 |
patrick b donnelly Citi | Hold | $72.0 | downgraded | Dec 11, 2023 |
andrew cooper Raymond James | Buy | $130.0 | reiterated | May 4, 2023 |
steven mah Cowen & Co. | Buy | $140.0 | maintained | Jul 26, 2021 |
tycho peterson J.P. Morgan | Sell | $80.0 | maintained | Jun 4, 2021 |
brian weinstein William Blair | Buy | None | reiterated | May 7, 2021 |
jack meehan Nephron | Hold | $90.0 | downgraded | Mar 26, 2020 |
john hsu Raymond James | Hold | None | downgraded | Mar 19, 2020 |
mark massaro BTIG | Buy | $75.0 | maintained | Nov 17, 2019 |
nicholas jansen Raymond James | Buy | $60.0 | maintained | Apr 3, 2018 |
john ransom Raymond James | Buy | $55.0 | reiterated | Mar 1, 2018 |
david westenberg Piper Sandler | Buy | $52.0 | upgraded | Jan 4, 2018 |
ryan daniels William Blair | Buy | None | reiterated | Jul 28, 2017 |
william bonello Craig-Hallum | Hold | $18.0 | downgraded | Oct 23, 2015 |
jeffrey frelick Canaccord Genuity | Buy | $34.0 | rated | Nov 10, 2014 |
zarak khurshid Wedbush | Hold | $20.0 | upgraded | Jul 23, 2014 |
j t haresco JMP Securities | Hold | None | initiatedcoverage | Dec 18, 2013 |
shaun rodriguez Cowen & Co. | Hold | None | rated | Oct 2, 2012 |
QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies and solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.
When did it IPO
0
Staff Count
7,000
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Mr. Douglas C. Bryant
Market Cap
$2.79B
In 2023, QDEL generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that QDEL's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
PI-USD
$102.69
FOXF-USD
$65.15
CALM-USD
$57.41
GH-USD
$22.66
PENN-USD
$18.61
HUBG-USD
$42.97